Q3 EPS Estimates for Haemonetics Boosted by Zacks Research

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research boosted their Q3 2026 earnings per share (EPS) estimates for shares of Haemonetics in a report released on Monday, February 17th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings per share of $1.33 for the quarter, up from their prior forecast of $1.31. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.48 EPS.

A number of other analysts have also recently weighed in on HAE. JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. Raymond James reaffirmed a “strong-buy” rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Needham & Company LLC lowered their price target on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Stock Down 0.7 %

Haemonetics stock opened at $62.98 on Thursday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of 24.79, a PEG ratio of 1.11 and a beta of 0.39. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97. The business has a fifty day moving average price of $72.61 and a 200-day moving average price of $76.66.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Hedge Funds Weigh In On Haemonetics

Institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics during the 4th quarter valued at about $25,000. Covestor Ltd raised its stake in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics during the 4th quarter valued at about $62,000. Nisa Investment Advisors LLC raised its stake in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 632 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.